RIBOPRO

About the deal

Oss, the Netherlands, 31st October 2024 — RIBOPRO, a leading technology and service provider, specializing in the development and production of mRNA and lipid nanoparticles, today proudly announced the successful closing of a Series A funding round. The round saw participation from existing investors Vlasroot, Rockstart, BOM Brabant Ventures, some private investors and new investor Mountainview Capital Partners.

“We are thrilled to announce the successful closing of our Series A funding round. This milestone is a testament to the hard work and dedication of our team, and we are incredibly grateful for the support of our investors,” said Sander van Asbeck, CEO and co-founder of RIBOPRO. “This funding will propel our mission to transform the industry with pioneering mRNA and LNP technologies and offer a variety of solutions to address the current challenges in the field. One of them being a cutting-edge and agile mRNA/LNP manufacturing machine, enabling the healthcare industry to prepare for both future pandemics as well as providing the ability to produce personalized cancer therapies in an agile and cost efficient way.